VIDEO: CAR T-cell therapy made in 1 day had good safety, efficacy in phase 1 trial

ByPaolo Caimi MD

ByErin Michael

Fact checked byMindy Valcarcel, MS

SAN DIEGO — A new chimeric antigen receptor T-cell therapy option made in less than a day may be a new option for patients with relapsed/refractory non-Hodgkin lymphoma, according to research presented at ASH Annual Meeting and Exposition.

Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, spoke with Healio about results from a phase 1 trial assessing the use of UF-Kure19 in 10 patients with non-Hodgkin lymphoma, which found that most patients had “good tolerance” to treatment.

“In terms of response, most patients had a response — eight out of 10 patients responded — with a good durability of responses on the patients that achieved complete remission,” he said.

Reference:

Wald D, et al. Abstract 94. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Caimi reports serving on the advisory board for ADC Therapeutics, Bristol Myers Squibb, Genentech, Luminary Therapeutics, Novartis and Synthekine; receiving honoraria from AbbVie, Arvinas, Recordati and Sobi; and research funding from AbbVie, Abcon, ADC Therapeutics, Arvinas, Bristol Myers Squibb, Genentech, Genmab, Luminary Therapeutics, Profound Bio, Recordati and Synthekine.

Take Homes in CAR T-cell Therapy

Read more

VIDEO: CAR T-cell therapy made in 1 day had good safety, efficacy in phase 1 trial

Reference:

Related Content